Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism
Hypoparathyroidism and osteoporosis can be treated with parathyroid hormone, but frequent injections are required. Here the authors develop a small-molecule agonist for the parathyroid hormone type I receptor that can be administered orally, and demonstrate its efficacy in rats.
Guardado en:
Autores principales: | Tatsuya Tamura, Hiroshi Noda, Eri Joyashiki, Maiko Hoshino, Tomoyuki Watanabe, Masahiko Kinosaki, Yoshikazu Nishimura, Tohru Esaki, Kotaro Ogawa, Taiji Miyake, Shinichi Arai, Masaru Shimizu, Hidetomo Kitamura, Haruhiko Sato, Yoshiki Kawabe |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modern problems of hyper- and hypoparathyroidism
por: Natalia G. Mokrysheva, et al.
Publicado: (2021) -
The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics
por: Neil Gittoes, et al.
Publicado: (2021) -
mTORC1 regulates PTHrP to coordinate chondrocyte growth, proliferation and differentiation
por: Bo Yan, et al.
Publicado: (2016) -
Risks and prediction of postoperative hypoparathyroidism due to thyroid surgery
por: Mustafa Ömer Yazıcıoğlu, et al.
Publicado: (2021) -
Extensive bilateral intracranial calcifications and seizure in iatrogenic hypoparathyroidism: A case report
por: Parikshit Chapagain, et al.
Publicado: (2021)